InsightfulValue
← Home

Ipsen
Ipsen

-4.64%

Pharma / Pharmaceuticals, Biotechnology


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Ipsen

πŸ“Š Get full analytics about Ipsen

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

Price
Live  
Overview
Ipsen is a French pharmaceutical company that specializes in the development and manufacture of medicines for rare diseases and specialty healthcare. The company was founded in 1929 by Henri Beaufour and is headquartered in Boulogne-Billancourt, France.
Ipsen's main focus is on areas such as oncology, neuroscience, and rare diseases. They have a strong global presence with products marketed in 115 countries and around 5,700 employees worldwide.
The company's goal is to improve the quality of life for patients with rare or debilitating diseases through their innovative treatments. They invest heavily in research and development, with approximately 20% of their sales revenues reinvested in this area.
Ipsen has a diverse portfolio of products including medications for conditions such as neuroendocrine tumors, spasticity, and gastrointestinal disorders. They also have a strong commitment to sustainability and ethical practices, with a focus on social responsibility and environmental protection.
In addition to their pharmaceutical business, Ipsen also has a presence in consumer healthcare with their Vichy, La Roche-Posay, and Dysport skin and beauty brands.
In recent years, Ipsen has expanded its international presence through strategic partnerships and acquisitions, including a joint venture with Teijin Pharma in Japan and the acquisition of Clementia Pharmaceuticals in Canada.
Overall, Ipsen continues to be a major player in the pharmaceutical industry, dedicated to providing life-changing treatments for patients around the world.
What is special about the company?
Ipsen

πŸ“ˆ Want to read more about Ipsen?

Sign up for free or log in

πŸ“ Join us and grab your copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

MS4gSGlzdG 9yeSBvZiBJ bm5vdmF0aW 9uOiBUaGUg SXBzZW4gY2 9tcGFueSBo YXMgYSByaW NoIGhpc3Rv cnkgb2YgaW 5ub3ZhdGlv biBhbmQgaG FzIGJlZW4g YXQgdGhlIG ZvcmVmcm9u dCBvZiBkZX ZlbG9waW5n IG5ldyBhbm QgYWR2YW5j ZWQgcGhhcm 1hY2V1dGlj YWwgcHJvZH VjdHMgZm9y IG92ZXIgOT AgeWVhcnMu IFRoZXkgaG F2ZSBhIHRy YWNrIHJlY2 9yZCBvZiBw aW9uZWVyaW 5nIG5ldyB0 cmVhdG1lbn RzIGZvciB2 YXJpb3VzIG Rpc2Vhc2Vz IGFuZCBoYX ZlIG1hZGUg YSBzaWduaW ZpY2FudCBp bXBhY3Qgb2 4gdGhlIG1l ZGljYWwgaW 5kdXN0cnku PGJyPjIuIE dsb2JhbCBQ cmVzZW5jZT ogSXBzZW4g aGFzIGEgZ2 xvYmFsIHBy ZXNlbmNlLC B3aXRoIG9w ZXJhdGlvbn MgaW4gbW9y ZSB0aGFuID MwIGNvdW50 cmllcyBhbm QgY29tbWVy Y2lhbCBhY3 Rpdml0aWVz IGluIG92ZX IgMTE1IGNv dW50cmllcy 4gVGhpcyBh bGxvd3MgdG hlbSB0byBy ZWFjaCBhIG xhcmdlIHBh dGllbnQgcG 9wdWxhdGlv biBhbmQgYn JpbmcgdGhl aXIgdHJlYX RtZW50cyB0 byBhIHdpZG UgcmFuZ2Ug b2YgbWFya2 V0cy48YnI+ My4gRm9jdX Mgb24gUmFy ZSBEaXNlYX NlczogSXBz ZW4gaGFzIG Egc3Ryb25n IGZvY3VzIG 9uIHJhcmUg YW5kIG5pY2 hlIGRpc2Vh c2VzLCB3aX RoIGEgZGVk aWNhdGVkIF JhcmUgRGlz ZWFzZXMgdW 5pdCB0aGF0 IHdvcmtzIH Rvd2FyZHMg ZGV2ZWxvcG luZyB0cmVh dG1lbnRzIG ZvciBkaXNl YXNlcyB0aG F0IGFmZmVj dCBhIHNtYW xsIG51bWJl ciBvZiBwZW 9wbGUuIFRo aXMgY29tbW l0bWVudCB0 byByYXJlIG Rpc2Vhc2Vz IGhhcyBsZW QgdG8gc2ln bmlmaWNhbn QgYWR2YW5j ZW1lbnRzIG luIHRyZWF0 bWVudCBvcH Rpb25zIGZv ciB0aGVzZS Bjb25kaXRp b25zLjxicj 40LiBQYXRp ZW50LUNlbn RlcmVkIEFw cHJvYWNoOi BJcHNlbiBo YXMgYSBwYX RpZW50LWNl bnRlcmVkIG FwcHJvYWNo LCBmb2N1c2 luZyBvbiB1 bmRlcnN0YW 5kaW5nIHRo ZSBuZWVkcy BhbmQgY29u Y2VybnMgb2 YgcGF0aWVu dHMgdG8gZG V2ZWxvcCB0 cmVhdG1lbn RzIHRoYXQg YmVzdCBtZW V0IHRoZWly IHJlcXVpcm VtZW50cy4g VGhleSBhbH NvIGFjdGl2 ZWx5IGVuZ2 FnZSB3aXRo IHBhdGllbn QgYWR2b2Nh Y3kgZ3JvdX BzIHRvIHJh aXNlIGF3YX JlbmVzcyBh bmQgc3VwcG 9ydCBmb3Ig cmFyZSBkaX NlYXNlcy48 YnI+NS4gU3 Ryb25nIFIm RCBQaXBlbG luZTogSXBz ZW4gaGFzIG Egcm9idXN0 IGFuZCBkaX ZlcnNlIFIm RCBwaXBlbG luZSwgd2l0 aCBhIGZvY3 VzIG9uIGRl dmVsb3Bpbm cgbmV3IGFu ZCBpbm5vdm F0aXZlIHRy ZWF0bWVudH MgaW4gYXJl YXMgc3VjaC BhcyBvbmNv bG9neSwgbm V1cm9zY2ll bmNlLCBhbm QgcmFyZSBk aXNlYXNlcy 4gVGhpcyBw aXBlbGluZS ByZWZsZWN0 cyB0aGUgY2 9tcGFueSdz IGNvbW1pdG 1lbnQgdG8g Y29udGludW 91cyBpbm5v dmF0aW9uIG FuZCBncm93 dGguPGJyPj YuIFN1c3Rh aW5hYmlsaX R5OiBJcHNl biBpcyBjb2 1taXR0ZWQg dG8gc3VzdG FpbmFibGUg ZGV2ZWxvcG 1lbnQgYW5k IHRha2VzIG 1lYXN1cmVz IHRvIG1pbm ltaXplIGl0 cyBlbnZpcm 9ubWVudGFs IGltcGFjdC BhbmQgcHJv bW90ZSByZX Nwb25zaWJs ZSBwcmFjdG ljZXMuIFRo aXMgaW5jbH VkZXMgcmVk dWNpbmcgdG hlaXIgY2Fy Ym9uIGZvb3 RwcmludCwg aW1wcm92aW 5nIGVuZXJn eSBlZmZpY2 llbmN5LCBh bmQgcHJvbW 90aW5nIGRp dmVyc2l0eS BhbmQgaW5j bHVzaW9uIH dpdGhpbiB0 aGVpciB3b3 JrZm9yY2Uu PGJyPjcuIE NvcnBvcmF0 ZSBTb2NpYW wgUmVzcG9u c2liaWxpdH k6IElwc2Vu IGlzIGRlZG ljYXRlZCB0 byBzdXBwb3 J0aW5nIGNv bW11bml0aW VzIGFuZCBn aXZpbmcgYm FjayB0byBz b2NpZXR5IH Rocm91Z2gg dmFyaW91cy Bzb2NpYWwg cmVzcG9uc2 liaWxpdHkg cHJvZ3JhbX MuIFRoaXMg aW5jbHVkZX MgaW5pdGlh dGl2ZXMgdG 8gaW1wcm92 ZSBhY2Nlc3 MgdG8gaGVh bHRoY2FyZS BpbiB1bmRl cnNlcnZlZC Bjb21tdW5p dGllcywgc3 VwcG9ydGlu ZyBoZWFsdG hjYXJlIHBy b2Zlc3Npb2 5hbHMsIGFu ZCByYWlzaW 5nIGF3YXJl bmVzcyBhYm 91dCByYXJl IGRpc2Vhc2 VzLjxicj44 LiBTdHJvbm cgQ3VsdHVy ZTogSXBzZW 4gaGFzIGEg c3Ryb25nIG N1bHR1cmUg dGhhdCB2YW x1ZXMgY29s bGFib3JhdG lvbiwgaW50 ZWdyaXR5LC BhbmQgY29t bWl0bWVudC B0byBleGNl bGxlbmNlLi BUaGVpciBl bXBsb3llZX MgYXJlIG1v dGl2YXRlZC B0byBtYWtl IGEgcG9zaX RpdmUgaW1w YWN0IGluIH RoZSB3b3Js ZCBhbmQgYX JlIGVuY291 cmFnZWQgdG 8gYnJpbmcg dGhlaXIgdW 5pcXVlIHBl cnNwZWN0aX ZlcyBhbmQg ZXhwZXJ0aX NlIHRvIHRo ZWlyIHdvcm suPGJyPjku IEF3YXJkcy BhbmQgUmVj b2duaXRpb2 5zOiBJcHNl biBoYXMgYm VlbiByZWNv Z25pemVkIG ZvciBpdHMg Y29udHJpYn V0aW9ucyBp biB0aGUgcG hhcm1hY2V1 dGljYWwgaW 5kdXN0cnkg d2l0aCBudW 1lcm91cyBh d2FyZHMgYW 5kIGFjY29s YWRlcy4gVG hlc2UgaW5j bHVkZSB0aG UgIkJlc3Qg RW1wbG95ZX IgQnJhbmQi IGF3YXJkIG J5IHRoZSBX b3JsZCBIUk QgQ29uZ3Jl c3MgYW5kIG JlaW5nIG5h bWVkIG9uZS BvZiB0aGUg Ik1vc3QgRX RoaWNhbCBD b21wYW5pZX MiIGJ5IHRo ZSBFdGhpc3 BoZXJlIElu c3RpdHV0ZS 48YnI+MTAu IFN0cmF0ZW dpYyBQYXJ0 bmVyc2hpcH M6IElwc2Vu IGhhcyBmb3 JtZWQgc3Ry YXRlZ2ljIH BhcnRuZXJz aGlwcyB3aX RoIG90aGVy IHBoYXJtYW NldXRpY2Fs IGNvbXBhbm llcyBhbmQg cmVzZWFyY2 ggaW5zdGl0 dXRpb25zIH RvIGFkdmFu Y2UgdGhlaX IgUiZEIGVm Zm9ydHMgYW 5kIGJyaW5n IGlubm92YX RpdmUgdHJl YXRtZW50cy B0byBtYXJr ZXQgZmFzdG VyLiBUaGlz IGNvbGxhYm 9yYXRpb24g YWxsb3dzIG ZvciB0aGUg c2hhcmluZy BvZiBrbm93 bGVkZ2UgYW 5kIHJlc291 cmNlcywgdW x0aW1hdGVs eSBiZW5lZm l0aW5nIHBh dGllbnRzIG FuZCBoZWFs dGhjYXJlIH Byb3ZpZGVy cy4=
What the company's business model?
Ipsen

πŸ“ˆ Want to read more about Ipsen?

Sign up for free or log in

βœ… Download "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” totally free!

VGhlIElwc2 VuIGNvbXBh bnkgaXMgYS BnbG9iYWwg YmlvcGhhcm 1hY2V1dGlj YWwgY29tcG FueSB0aGF0 IGZvY3VzZX Mgb24gZGV2 ZWxvcGluZy BhbmQgY29t bWVyY2lhbG l6aW5nIGlu bm92YXRpdm UgcHJvZHVj dHMgZm9yIH BhdGllbnRz IHdpdGggc2 VyaW91cyBk aXNlYXNlcy 4gVGhlaXIg YnVzaW5lc3 MgbW9kZWwg aXMgY2VudG VyZWQgYXJv dW5kIHRocm VlIGtleSBl bGVtZW50cz ogcmVzZWFy Y2ggYW5kIG RldmVsb3Bt ZW50IChSJk QpLCBjb21t ZXJjaWFsaX phdGlvbiwg YW5kIHN1c3 RhaW5hYmls aXR5Ljxicj 4xLiBSZXNl YXJjaCBhbm QgRGV2ZWxv cG1lbnQgKF ImRCk6PGJy Pklwc2VuIG ludmVzdHMg aGVhdmlseS BpbiBSJkQs IHdpdGggYW 4gYWltIHRv IGRldmVsb3 Agbm92ZWwg dGhlcmFwaW VzIGFuZCB0 cmVhdG1lbn RzIGZvciBk aXNlYXNlcy B3aXRoIGhp Z2ggdW5tZX QgbWVkaWNh bCBuZWVkcy 4gVGhleSBo YXZlIGEgc3 Ryb25nIGlu LWhvdXNlIF ImRCB0ZWFt IGFuZCBhbH NvIGNvbGxh Ym9yYXRlIH dpdGggYWNh ZGVtaWMgaW 5zdGl0dXRp b25zLCBiaW 90ZWNoIGNv bXBhbmllcy wgYW5kIG90 aGVyIHBhcn RuZXJzIHRv IGlkZW50aW Z5IGFuZCBk ZXZlbG9wIH Byb21pc2lu ZyBkcnVnIG NhbmRpZGF0 ZXMuPGJyPj IuIENvbW1l cmNpYWxpem F0aW9uOjxi cj5JcHNlbi BoYXMgYSBn bG9iYWwgY2 9tbWVyY2lh bGl6YXRpb2 4gc3RyYXRl Z3ksIHdpdG ggYSBwcmVz ZW5jZSBpbi Btb3JlIHRo YW4gMTE1IG NvdW50cmll cy4gVGhleS BoYXZlIGEg ZGl2ZXJzaW ZpZWQgcG9y dGZvbGlvIG 9mIHByb2R1 Y3RzIGluIG RpZmZlcmVu dCB0aGVyYX BldXRpYyBh cmVhcyBzdW NoIGFzIG5l dXJvbG9neS wgZW5kb2Ny aW5vbG9neS wgYW5kIG9u Y29sb2d5Li BUaGV5IHVz ZSBhIGNvbW JpbmF0aW9u IG9mIGRpcm VjdCBzYWxl cywgcGFydG 5lcnNoaXBz LCBhbmQgbG ljZW5zaW5n IGFncmVlbW VudHMgdG8g cmVhY2ggcG F0aWVudHMg aW4gZGlmZm VyZW50IHJl Z2lvbnMuPG JyPjMuIFN1 c3RhaW5hYm lsaXR5Ojxi cj5BcyBhIG hlYWx0aGNh cmUgY29tcG FueSwgSXBz ZW4gaXMgY2 9tbWl0dGVk IHRvIHN1c3 RhaW5hYmls aXR5IGFuZC Bjb3Jwb3Jh dGUgc29jaW FsIHJlc3Bv bnNpYmlsaX R5LiBUaGV5 IGhhdmUgYS BzdHJvbmcg ZXRoaWNhbC Bjb2RlIG9m IGNvbmR1Y3 QgYW5kIGFy ZSBkZWRpY2 F0ZWQgdG8g cHJvbW90aW 5nIGFjY2Vz cyB0byBoZW FsdGhjYXJl IGZvciBhbG wgdGhyb3Vn aCB2YXJpb3 VzIGluaXRp YXRpdmVzLC BpbmNsdWRp bmcgcGF0aW VudCBhc3Np c3RhbmNlIH Byb2dyYW1z LCBkaXNlYX NlIGF3YXJl bmVzcyBjYW 1wYWlnbnMs IGFuZCBwYX J0bmVyc2hp cHMgd2l0aC BwYXRpZW50 IG9yZ2FuaX phdGlvbnMu PGJyPk92ZX JhbGwsIElw c2VuJ3MgYn VzaW5lc3Mg bW9kZWwgZm 9jdXNlcyBv biBkZXZlbG 9waW5nIGFu ZCBjb21tZX JjaWFsaXpp bmcgaW5ub3 ZhdGl2ZSB0 cmVhdG1lbn RzIHRvIGlt cHJvdmUgdG hlIGxpdmVz IG9mIHBhdG llbnRzLCB3 aGlsZSBhbH NvIGVuc3Vy aW5nIHRoZS BzdXN0YWlu YWJpbGl0eS BhbmQgZ3Jv d3RoIG9mIH RoZSBjb21w YW55Lg==
Is AI a threat?
AI can indeed pose several potential threats to Ipsen’s products, services, and competitive positioning, though the specific impact would depend on various factors, including the company’s strategic responses and developments in the AI landscape.
1. Substitution: AI-driven technologies such as advanced diagnostics, personalized medicine, and automated healthcare solutions could potentially replace some of the therapeutic areas where Ipsen operates. For example, AI could lead to breakthroughs in targeted therapies or more effective treatments that could supplant existing Ipsen products if the company does not innovate quickly enough.
2. Disintermediation: AI can enable direct-to-consumer healthcare services and telemedicine platforms, potentially reducing the need for traditional pharmaceutical sales channels. This shift could disrupt Ipsen’s traditional distribution methods and customer engagement strategies, forcing the company to adapt or risk losing market share.
3. Margin Pressure: AI can improve operational efficiencies and cost-effectiveness in drug development and manufacturing. If competitors leverage AI more effectively, they may reduce their costs and offer products at lower prices, which could pressure Ipsen’s margins. Additionally, AI-driven personalized medicine could drive up R&D costs, impacting profitability if Ipsen fails to keep pace with such innovations.
Overall, while AI presents opportunities for enhancing healthcare, it also necessitates that Ipsen actively innovate and adapt to avoid being adversely affected in these areas.
1221506
Sensitivity to interest rates
The sensitivity of Ipsen’s earnings, cash flow, and valuation to changes in interest rates can be analyzed through several lenses:
1. Earnings Sensitivity: Higher interest rates can increase the cost of borrowing for Ipsen, particularly if the company relies on debt to finance its operations or R&D activities. This can lead to reduced profitability if the higher interest expenses outweigh the company’s earnings growth. Conversely, lower interest rates can decrease borrowing costs, improving earnings.
2. Cash Flow Sensitivity: Interest rates affect cash flow primarily through the cost of existing debt and any new financing arrangements. If Ipsen has variable-rate debt, rising interest rates may reduce cash flow due to increased interest payments. On the other hand, lower rates improve cash flows, as less cash is outlaid for interest, allowing for more funds to be directed towards investment or dividends.
3. Valuation Sensitivity: Interest rates play a crucial role in discounting future cash flows when valuing a company. An increase in interest rates raises the discount rate, which can significantly lower the present value of Ipsen’s future cash flows, leading to a decrease in its market valuation. In contrast, a decrease in interest rates lowers the discount rate, enhancing the present value of future cash flows and supporting a higher valuation.
Overall, changes in interest rates have a multifaceted impact on Ipsen’s financial performance and market valuation. The exact sensitivity would depend on the company’s leverage, the structure of its debt, and the overall economic environment.
Interesting facts about the company
Ipsen

πŸ“ˆ Want to read more about Ipsen?

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvSU hyaG9SaG9m NmozQWVxZm 1Ta2Qud2Vi cCIgYWx0PS JJcHNlbiIg dGl0bGU9Ik lwc2VuIiAg Y2xhc3M9Im ltZy1mbHVp ZCIgaGVpZ2 h0PTkwIHdp ZHRoPTkwIG xvYWRpbmc9 J2xhenknIH N0eWxlPSdi b3JkZXItcm FkaXVzOiA2 cHg7Jz4KCi AgICAgICAg ICAgICAgIC AgICAgPGRp diBzdHlsZT 0nZmxleDog MTsgdGV4dC 1hbGlnbjog Y2VudGVyOy BtYXJnaW4t bGVmdDogNX B4Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID xwIHN0eWxl PSdmb250LX NpemU6IDI2 cHg7IGNvbG 9yOiAjMzMz OyBtYXJnaW 4tYm90dG9t OiAxNXB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Dwn5OIIFdh bnQgdG8gcm VhZCBtb3Jl IGFib3V0IE lwc2VuPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TnSBKb2lu IHVzIGFuZC BncmFiIHlv dXIgY29weS BvZiA8aT4i VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr cyI8L2k+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvcD4KCi AgICAgICAg ICAgICAgIC AgICAgICAg IDwhLS0KIC AgICAgICAg ICAgICAgIC AgICAgICAg PGRpdiBzdH lsZT0nbWFy Z2luLXRvcD ogMTJweDsg Zm9udC1zaX plOiAxM3B4 OyBjb2xvcj ogIzQ0NDsn PgogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg U2lnbiB1cC Bub3cgYW5k IGdldCBvdX IgZnJlZSBl Qm9vayAKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIDxiPl RoZSBDaGVj a2xpc3QgVm FsdWUgSW52 ZXN0b3Ig4o CUIEEgU21h cnRlciBXYX kgdG8gUGlj ayBTdG9ja3 M8L2I+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC EtLQogICAg ICAgICAgIC AgICAgICAg ICAgICA8ZG l2IHN0eWxl PSdtYXJnaW 4tdG9wOiAx NnB4OyBmb2 50LXNpemU6 IDE0cHg7IG NvbG9yOiAj NDQ0OyBmb2 50LWZhbWls eTogLWFwcG xlLXN5c3Rl bSwgQmxpbm tNYWNTeXN0 ZW1Gb250LC BTZWdvZSBV SSwgUm9ib3 RvLCBIZWx2 ZXRpY2EgTm V1ZSwgc2Fu cy1zZXJpZj sgbGluZS1o ZWlnaHQ6ID EuNjsnPgog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgSGF2 ZSB5b3UgaG VhcmQgYWJv dXQgb3VyIH Nob3J0IDxz dHJvbmcgc3 R5bGU9J2Zv bnQtd2VpZ2 h0OiA2MDA7 Jz5EYWlseS BWaWRlbyBO ZXdzbGV0dG VyPC9zdHJv bmc+PwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGEgaH JlZj0naHR0 cHM6Ly93d3 cuaW5zaWdo dGZ1bHZhbH VlLmNvbS9u ZXdzbGV0dG VyLnBocCcg dGFyZ2V0PS dfYmxhbmsn IHN0eWxlPS djb2xvcjog IzAwN0JGRj sgdGV4dC1k ZWNvcmF0aW 9uOiBub25l OyBmb250LX dlaWdodDog NTAwOyBtYX JnaW4tbGVm dDogNnB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgRmlu ZCBvdXQgbW 9yZQogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9hPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgLS0+CiAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgIAogIC AgICAgIAog ICAgICAgID xzcGFuIGNs YXNzPSdibH VycmVkLXRl eHQnPgogIC AgICAgICAg ICBMU0JKY0 hObGJpIEJw Y3lCaElHZH MgYjJKaGJD QmlhVyA5d2 FHRnliV0Zq IFpYVjBhV0 5oYkMgQmpi MjF3WVc1NS BJSE53WldO cFlXIHhwZW 1sdVp5QnAg YmlCMGFHVW daRyBWMlpX eHZjRzFsIG JuUWdZVzVr SUggQnliMl IxWTNScCBi MjRnYjJZZ2 JXIFZrYVdO cGJtVnogSU dadmNpQjBh RyBVZ2RISm xZWFJ0IFpX NTBJRzltSU ggSmhjbVVn WVc1ayBJSE 5sY21sdmRY IE1nWkdsel pXRnogWlhN dVBHSnlQaS AwZ1ZHaGxJ R052IGJYQm hibmtnZDIg RnpJR1p2ZF c1ayBaV1Fn YVc0Z01UIG t5T1NCaWVT QkkgWlc1eW FTQmhibSBR Z1NtVmhibT VsIElFbHdj MlZ1SUcgbH VJRkJoY21s eiBMQ0JHY2 1GdVkyIFV1 UEdKeVBpMG cgU1hCelpX NGdhVyA1cG RHbGhiR3g1 IElHWnZZM1 Z6WlcgUWdi MjRnZEdobC BJSEJ5YjJS MVkzIFJwYj I0Z2IyWWcg YUc5eWJXOX VaWCBNZ1pt OXlJRzFsIF pHbGpZV3dn ZFggTmxMQ0 JpZFhRZyBi R0YwWlhJZ1 pYIGh3WVc1 a1pXUWcgYV c1MGJ5QnZk RyBobGNpQj BhR1Z5IFlY QmxkWFJwWX kgQmhjbVZo Y3lCcCBibU 5zZFdScGJt IGNnWlc1a2 IyTnkgYVc1 dmJHOW5lUy B3Z2JtVjFj bTlzIGIyZD VMQ0JoYm0g UWdiMjVqYj J4diBaM2t1 UEdKeVBpID BnU1c0Z01U azMgTkN3Z1 NYQnpaVyA0 Z2QyRnpJSF JvIFpTQm1h WEp6ZEMgQk ZkWEp2Y0dW aCBiaUJqYj Ixd1lXIDU1 SUhSdklHeG ggZFc1amFD QnlaVyBOdm JXSnBibUZ1 IGRDQm9kVz FoYmkgQnBi bk4xYkdsdS BJR1p2Y2lC MGFHIFVnZE hKbFlYUnQg Wlc1MElHOW 1JRyBScFlX SmxkR1Z6IE xqeGljajR0 SUYgUm9aU0 JqYjIxdyBZ VzU1SUdoaG N5IEJoSUhO MGNtOXUgWn lCd2NtVnpa VyA1alpTQn BiaUJHIGNt RnVZMlVzSU cgRnpJSGRs Ykd3ZyBZWE 1nYTJWNUlH IDFoY210bG RITWcgYVc0 Z1RtOXlkRy BnZ1FXMWxj bWxqIFlTd2 dSWFZ5YjMg QmxMQ0JoYm 1RZyBRWE5w WVM0OFluIE krTFNCSmNI TmwgYmlCcG N5QnJibSA5 M2JpQm1iM0 lnIGFYUnpJ SE4wY20gOX VaeUJqYjIx dCBhWFJ0Wl c1MElIIFJ2 SUhKbGMyVm ggY21Ob0lH RnVaQyBCa1 pYWmxiRzl3 IGJXVnVkQ3 dnZDIgbDBh Q0JoY0hCeS BiM2hwYldG MFpXIHg1SU Rjd01DQnQg YVd4c2FXOX VJRyBWMWNt OXpJR2x1IG RtVnpkR1Zr SUcgbHVJRk ltUkNCaCBi bTUxWVd4c2 VTIDQ4WW5J K0xTQlUgYU dVZ1kyOXRj RyBGdWVTQm 9ZWE1nIFlT Qm5iRzlpWV cgd2dibVYw ZDI5eSBheU J2WmlCeVpY IE5sWVhKam FDQmggYm1R Z1pHVjJaVy B4dmNHMWxi blFnIFkyVn VkR1Z5Y3kg d2dkMmwwYU NCMCBhR1Vn YkdGeVoyIF Z6ZENCbVlX TnAgYkdsMG VTQnNiMiBO aGRHVmtJR2 x1IElFeGxj eUJWYkcgbH pMQ0JHY21G dSBZMlV1UE dKeVBpIDBn U1hCelpXNG cgYUdGeklH RWdjRyA5eW RHWnZiR2x2 IElHOW1JRz kyWlggSWdN akFnY0hKdi BaSFZqZEhN c0lHIEZ1Wk NCcGN5Qmog YjI1MGFXNT FiMyBWemJI a2daWGh3IF lXNWthVzVu SUcgbDBjeU J3Y205ayBk V04wSUhCcG NHIFZzYVc1 bElIUm8gY2 05MVoyZ2dZ MiA5c2JHRm liM0poIGRH bHZibk1nWV cgNWtJSEJo Y25SdSBaWE p6YUdsd2N5 IDQ4WW5JK0 xTQlUgYUdV Z1kyOXRjRy BGdWVTQm9Z WE1nIFlTQn pkSEp2Ym0g Y2dabTlqZF hNZyBiMjRn YzNWemRHIE ZwYm1GaWFX eHAgZEhrZ1 lXNWtJRyBO dmNuQnZjbU YwIFpTQnpi Mk5wWVcgd2 djbVZ6Y0c5 dSBjMmxpYV d4cGRIIGtz SUhkcGRHZ2 cgYVc1cGRH bGhkRyBsMl pYTWdhVzRn IGNHeGhZMl VnZEcgOGdj bVZrZFdObC BJR2wwY3lC bGJuIFpwY2 05dWJXVnUg ZEdGc0lHbH RjRyBGamRD QmhibVFnIG NISnZiVzkw WlMgQmthWF psY25OcCBk SGtnWVc1a0 lHIGx1WTJ4 MWMybHYgYm k0OFluSStM UyBCSmNITm xiaUJvIFlY TWdjbVZqWl cgbDJaV1Fn Y21WaiBiMm R1YVhScGIy IDRnWVc1a0 lHRjMgWVhK a2N5Qm1iMy BJZ2FYUnpJ SGR2IGNtc2 dhVzRnY20g RnlaU0JrYV hObCBZWE5s Y3l3Z2FXID VqYkhWa2FX NW4gSUdKbG FXNW5JRyA1 aGJXVmtJRz l1IFpTQnZa aUIwYUcgVW dWRzl3SURF dyBNQ0JOYj NOMElFIGx1 Ym05MllYUn AgZG1VZ1Ey OXRjRyBGdW FXVnpJR2x1 IElIUm9aU0 JYYjMgSnNa Q0JpZVNCRy BiM0ppWlhN Z2FXIDRnTW pBeE55ND0K ICAgICAgIC A8L3NwYW4+ CiAgICAgIC AgCiAgICAg ICAg
See Company Q&A
Ipsen

πŸ“Š Get full analytics about Ipsen

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal